Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.
Tirzepatide shows low rates of heart rhythm problems overall, suggesting the drug may be safer than initial concerns suggested for weight management.
This PubMed record reports: Although higher odds of overall arrhythmias were observed, event rates were low and the findings should be interpreted cautiously. The finding is retained for rapid triage and requires downstream evidence review before clinical interpretation.
What the study was
- Study design
- Randomized controlled trial
- Category
- Prevention
- Maturity
- Validated
- Journal
- Journal of the American Heart Association
Why it surfaced
Retained because its randomized controlled trial evidence is relevant to Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; scoring is conservative for the available metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.